Dr. Goy on Future Treatment Approaches in MCL

Video

In Partnership With:

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses future treatment approaches in patients with mantle cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses future treatment approaches in patients with mantle cell lymphoma (MCL).

BTK inhibitors like ibrutinib (Imbruvica) and, most recently, the second-generation inhibitor acalabrutinib (Calquence) have been established as the standard of care for patients in the relapsed/refractory setting. In the salvage setting, these agents are also showing benefit in combination with rituximab (Rituxan), says Goy. He also predicts that the combination of ibrutinib and venetoclax (Venclexta) is going to move to the frontline setting.

Moreover, the R-BAC regimen (rituximab, cytarabine, and bendamustine) is leading to impressive responses outside of a clinical trial, even in patients with relapsed disease. Goy adds that if the dose of cytarabine is adjusted, this regimen is also feasible in elderly, frail patients.

Moving forward, it is going to be crucial to do a full pathology of the patient’s lymphoma to see if they have high-risk markers, including p53 and Ki-67 mutations.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine